PET/MR Scan for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new imaging method, which combines PET and MR scans with a special tracer ([68Ga]Ga-PentixaFor), can better diagnose Multiple Myeloma, a cancer that mainly affects bones. Researchers hope this new scan will be more precise than current imaging tests. The trial seeks individuals diagnosed with Multiple Myeloma, specifically those who haven't received treatment beyond the first course. Eligible participants must be able to lie still for certain imaging tests. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could improve diagnostic methods for future patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this PET/MR scan is safe for diagnosing Multiple Myeloma?
Research has shown that [68Ga]Ga-PentixaFor, a new substance used in PET/MR scans, may help doctors more easily detect certain cancers, such as lymphoma and possibly multiple myeloma. In earlier studies, this substance created clearer images of cancer in the body, allowing doctors to more accurately assess how the disease affects bones and other organs.
Regarding safety, patients have generally tolerated [68Ga]Ga-PentixaFor well in scans. Studies using similar scanning methods have reported no major serious side effects. Improvements in the production of this substance have ensured it meets medical standards, suggesting it is safe for use in scans.
In summary, while ongoing research continues, [68Ga]Ga-PentixaFor has so far been safe for use in imaging tests, with no significant safety concerns reported.12345Why are researchers excited about this trial?
Researchers are excited about the investigational imaging technique using [68Ga]Ga-PentixaFor for multiple myeloma because it represents a potentially groundbreaking advancement in diagnostic imaging. Unlike standard imaging methods, such as MRI or CT scans, this technique specifically targets the CXCR4 receptor, which is often overexpressed in multiple myeloma cells. This targeted approach could lead to more precise detection and characterization of the disease, offering valuable insights for diagnosis, prognosis, and therapy planning. By honing in on the CXCR4 receptor, researchers anticipate that [68Ga]Ga-PentixaFor PET/MR imaging might provide clearer, more informative images, potentially leading to earlier and more accurate treatment decisions.
What evidence suggests that this PET/MR scan is effective for diagnosing Multiple Myeloma?
Research has shown that a new imaging method using [68Ga]Ga-PentixaFor holds promise for diagnosing multiple myeloma, a type of blood cancer. In this trial, participants will undergo the investigational imaging modality, CXCR4-targeted [68Ga]Ga-PentixaFor PET/MR, to assess its diagnostic, prognostic, and therapeutic value. Studies suggest this method can better predict disease progression in newly diagnosed patients. [68Ga]Ga-PentixaFor targets a protein called CXCR4, found in large amounts in multiple myeloma cells, which helps the imaging method clearly highlight affected areas. As a result, doctors might more accurately determine disease spread compared to standard imaging methods. Early findings indicate that this new technique could enhance how doctors determine the disease stage and monitor its progress.14678
Who Is on the Research Team?
Patrick Veit-Haibach, MD
Principal Investigator
University Health Network, Toronto
Are You a Good Fit for This Trial?
This trial is for individuals diagnosed with Multiple Myeloma, a cancer affecting the bones. It's designed to see if a new PET/MR scan using [68Ga]Ga-PentixaFor can give more precise diagnostic information than current standard imaging tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Staging
Participants undergo initial staging with CXCR4-targeted [68Ga]Ga-PentixaFor PET/MR imaging compared to standard imaging methods
Treatment Decision Making
Evaluation of how CXCR4 PET/MR imaging influences treatment decisions, including preconditioning and stem cell transplantation considerations
Response Assessment
Assessment of therapy response using CXCR4 PET/MR imaging to guide follow-up and supportive therapy decisions
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adverse events related to radiopharmaceutical administration
What Are the Treatments Tested in This Trial?
Interventions
- [68Ga]Ga-PentixaFor
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor